Search

Your search keyword '"Lems, Willem F."' showing total 995 results
Start Over Author "Lems, Willem F."
995 results on '"Lems, Willem F."'

3. [18F]Fluoride PET provides distinct information on disease activity in ankylosing spondylitis as compared to MRI and conventional radiography

Author

de Jongh, Jerney, Verweij, Nicki J. F., Yaqub, Maqsood, van Denderen, Christiaan J., van der Horst-Bruinsma, Irene E., Bot, Joost C. J., Boden, Bouke J. H., Hemke, Robert, Smithuis, Frank F., Lems, Willem F., Lammertsma, Adriaan A., Voskuyl, Alexandre E., Boers, Maarten, Zwezerijnen, Gerben J. C., and van der Laken, Conny J.

Published
2023
Full Text
View/download PDF

5. Post-COVID condition in patients with inflammatory rheumatic diseases: a prospective cohort study in the Netherlands

Author

Boekel, Laura, Atiqi, Sadaf, Leeuw, Maureen, Hooijberg, Femke, Besten, Yaëlle R., Wartena, Rosa, Steenhuis, Maurice, Vogelzang, Erik, Webers, Casper, Boonen, Annelies, Gerritsen, Martijn, Lems, Willem F, Tas, Sander W, van Vollenhoven, Ronald F, Voskuyl, Alexandre E, van der Horst-Bruinsma, Irene, Nurmohamed, Mike, Rispens, Theo, and Wolbink, Gertjan

Published
2023
Full Text
View/download PDF

7. Stratified exercise therapy does not improve outcomes compared with usual exercise therapy in people with knee osteoarthritis (OCTOPuS study): a cluster randomised trial

Author

Knoop, Jesper, Dekker, Joost, van Dongen, Johanna M, van der Leeden, Marike, de Rooij, Mariette, Peter, Wilfred FH, de Joode, Willemijn, van Bodegom-Vos, Leti, Lopuhaä, Nique, Bennell, Kim L, Lems, Willem F, van der Esch, Martin, Vliet Vlieland, Thea PM, and Ostelo, Raymond WJG

Published
2022
Full Text
View/download PDF

8. Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies

Author

de Jongh, Rivka, van de Sandt, Carolien, Kuijper, Lisan, Duurland, Mariel, Hagen, Ruth, van den Dijssel, Jet, Kreher, Christine, Bos, Amelie, Palomares Cabeza, Viriginia, Konijn, Veronique, Elias, George, Vallejo, Juan, van Gils, Marrit, Ashhurst, Tom, Nejentsev, Sergey, Mirfazeli, Elham, Boekel, Laura, Stalman, Eileen W, Wieske, Luuk, Hooijberg, Femke, van Dam, Koos P J, Besten, Yaëlle R, Kummer, Laura Y L, Steenhuis, Maurice, van Kempen, Zoé L E, Killestein, Joep, Volkers, Adriaan G, Tas, Sander W, van der Kooi, Anneke J, Raaphorst, Joost, Löwenberg, Mark, Takkenberg, R Bart, D'Haens, Geert R A M, Spuls, Phyllis I, Bekkenk, Marcel W, Musters, Annelie H, Post, Nicoline F, Bosma, Angela L, Hilhorst, Marc L, Vegting, Yosta, Bemelman, Frederike J, Voskuyl, Alexandre E, Broens, Bo, Parra Sanchez, Agner, van Els, Cécile A C M, de Wit, Jelle, Rutgers, Abraham, de Leeuw, Karina, Horváth, Barbara, Verschuuren, Jan J G M, Ruiter, Annabel M, van Ouwerkerk, Lotte, van der Woude, Diane, Allaart, Cornelia F, Teng, Y K Onno, van Paassen, Pieter, Busch, Matthias H, Jallah, Papay B P, Brusse, Esther, van Doorn, Pieter A, Baars, Adája E, Hijnen, Dirk Jan, Schreurs, Corine R G, van der Pol, W Ludo, Goedee, H Stephan, Vogelzang, Erik H, Leeuw, Maureen, Atiqi, Sadaf, van Vollenhoven, Ronald, Gerritsen, Martijn, van der Horst-Bruinsma, Irene E, Lems, Willem F, Nurmohamed, Mike T, Boers, Maarten, Keijzer, Sofie, Keijser, Jim, Boogaard, Arend, Cristianawati, Olvi, ten Brinke, Anja, Verstegen, Niels J M, Zwinderman, Koos A H, van Ham, S Marieke, Rispens, Theo, Kuijpers, Taco W, Wolbink, Gertjan, and Eftimov, Filip

Published
2022
Full Text
View/download PDF

11. Osteoporotic Fractures: Diagnosis, Evaluation, and Significance From the International Working Group on DXA Best Practices

Author

Khan, Aliya A., Slart, Riemer H.J.A., Ali, Dalal S., Bock, Oliver, Carey, John J., Camacho, Pauline, Engelke, Klaus, Erba, Paola A., Harvey, Nicholas C., Lems, Willem F., Morgan, Sarah, Moseley, Kendall F., O’Brien, Christopher, Probyn, Linda, Punda, Marija, Richmond, Bradford, Schousboe, John T., Shuhart, Christopher, Ward, Kate A., and Lewiecki, E. Michael

Abstract

Osteoporotic fractures, also known as fragility fractures, are reflective of compromised bone strength and are associated with significant morbidity and mortality. Such fractures may be clinically silent, and others may present clinically with pain and deformity at the time of the injury. Unfortunately, and even at the time of detection, most individuals sustaining fragility fractures are not identified as having underlying metabolic bone disease and are not evaluated or treated to reduce the incidence of future fractures. A multidisciplinary international working group with representation from international societies dedicated to advancing the care of patients with metabolic bone disease has developed best practice recommendations for the diagnosis and evaluation of individuals with fragility fractures. A comprehensive narrative review was conducted to identify key articles on fragility fractures and their impact on the incidence of further fractures, morbidity, and mortality. This document represents consensus among the supporting societies and harmonizes best practice recommendations consistent with advances in research. A fragility fracture in an adult is an important predictor of future fractures and requires further evaluation and treatment of the underlying osteoporosis. It is important to recognize that most fragility fractures occur in patients with bone mineral density T scores higher than −2.5, and these fractures confirm the presence of skeletal fragility even in the presence of a well-maintained bone mineral density. Fragility fractures require further evaluation with exclusion of contributing factors for osteoporosis and assessment of clinical risk factors for fracture followed by appropriate pharmacological intervention designed to reduce the risk of future fracture. Because most low-trauma vertebral fractures do not present with pain, dedicated vertebral imaging and review of past imaging is useful in identifying fractures in patients at high risk for vertebral fractures. Given the importance of fractures in confirming skeletal fragility and predicting future events, it is recommended that an established classification system be used for fracture identification and reporting.

Published
2024
Full Text
View/download PDF

12. Estimating the Time to Benefit for Preventive Drugs with the Statistical Process Control Method: An Example with Alendronate

Author

van de Glind, Esther MM, Willems, Hanna C, Eslami, Saeid, Abu-Hanna, Ameen, Lems, Willem F, Hooft, Lotty, de Rooij, Sophia E, Black, Dennis M, and van Munster, Barbara C

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Trials and Supportive Activities, Clinical Research, Prevention, Aging, Good Health and Well Being, Alendronate, Bone Density, Female, Fractures, Bone, Humans, Middle Aged, Osteoporosis, Postmenopausal, Risk, Spinal Fractures, Survival Analysis, Time Factors, Pharmacology and Pharmaceutical Sciences, Geriatrics, Clinical sciences, Pharmacology and pharmaceutical sciences
Abstract

BackgroundFor physicians dealing with patients with a limited life expectancy, knowing the time to benefit (TTB) of preventive medication is essential to support treatment decisions.ObjectiveThe aim of this study was to investigate the usefulness of statistical process control (SPC) for determining the TTB in relation to fracture risk with alendronate versus placebo in postmenopausal women.MethodsWe performed a post hoc analysis of the Fracture Intervention Trial (FIT), a randomized, controlled trial that investigated the effect of alendronate versus placebo on fracture risk in postmenopausal women. We used SPC, a statistical method used for monitoring processes for quality control, to determine if and when the intervention group benefited significantly more than the control group. SPC discriminated between the normal variations over time in the numbers of fractures in both groups and the variations that were attributable to alendronate. The TTB was defined as the time point from which the cumulative difference in the number of clinical fractures remained greater than the upper control limit on the SPC chart.ResultsFor the total group, the TTB was defined as 11 months. For patients aged ≥70 years, the TTB was 8 months [absolute risk reduction (ARR) = 1.4%]; for patients aged

Published
2016

13. Peripheral quantitative computed tomography in the assessment of bone mineral density in anti-TNF-treated rheumatoid arthritis and ankylosing spondylitis patients

Author

Juhász, Balázs, Gulyás, Katalin, Horváth, Ágnes, Végh, Edit, Pusztai, Anita, Szentpétery, Ágnes, Pethő, Zsófia, Bodnár, Nóra, Hamar, Attila, Bodoki, Levente, Bhattoa, Harjit Pal, Szekanecz, Éva, Hodosi, Katalin, Domján, Andrea, Szamosi, Szilvia, Horváth, Csaba, Szántó, Sándor, Szűcs, Gabriella, Raterman, Hennie G., Lems, Willem F., FitzGerald, Oliver, and Szekanecz, Zoltán

Published
2021
Full Text
View/download PDF

15. Associations of vascular and bone status in arthritis patients

Author

Pusztai, Anita, Hamar, Attila, Czókolyová, Monika, Gulyás, Katalin, Horváth, Ágnes, Végh, Edit, Pethő, Zsófia, Szamosi, Szilvia, Balogh, Emese, Bodnár, Nóra, Bodoki, Levente, Szentpétery, Ágnes, Bhattoa, Harjit Pal, Kerekes, György, Juhász, Balázs, Szekanecz, Éva, Hodosi, Katalin, Domján, Andrea, Szántó, Sándor, Raterman, Hennie G., Lems, Willem F., Szekanecz, Zoltán, and Szűcs, Gabriella

Published
2021
Full Text
View/download PDF

20. Repair of joint damage in patients with rheumatoid arthritis does not relate to previous suppression of inflammation: a subanalysis after 8 years treat-to-target in the BeSt-trial

Author

van der Pol, Joy Ardjuna, primary, Akdemir, Gülşah, additional, van den Broek, Marianne, additional, Dirven, Linda, additional, Kerstens, Pit J S M, additional, Lems, Willem F, additional, Markusse, Iris M, additional, Huizinga, Tom W J, additional, and Allaart, Cornelia F, additional

Published
2023
Full Text
View/download PDF

24. Frequency of joint inflammation is associated with local joint damage progression in rheumatoid arthritis despite long-term targeted treatment

Author

Heckert, Sascha L, primary, Bergstra, Sytske Anne, additional, Goekoop-Ruiterman, Yvonne P M, additional, Güler-Yüksel, Melek, additional, Lems, Willem F, additional, Matthijssen, Xanthe M E, additional, van Oosterhout, Maikel, additional, Huizinga, Tom W J, additional, and Allaart, Cornelia F, additional

Published
2023
Full Text
View/download PDF

27. Increased fracture risk and fracture prevention

Author

Krul-Poel, Yvonne H. M., Vrijlandt, Patrick J. W. S., Elders, Petra J. M., van den Bergh, Joop P., Lems, Willem F., de Jongh, Renate T., General practice, ACS - Diabetes & metabolism, APH - Health Behaviors & Chronic Diseases, Rheumatology, AII - Inflammatory diseases, AMS - Musculoskeletal Health, AMS - Tissue Function & Regeneration, Internal medicine, AMS - Ageing & Vitality, and Amsterdam Gastroenterology Endocrinology Metabolism

Abstract

An increased fracture risk is a common chronic condition leading to a rising number of fractures, which are injurious to patients and costly to the health care system. Effective diagnostic and treatment options are available for primary and secondary prevention. In this article, we will answer specific practical questions with respect to increased fracture risk and fracture prevention. Topics discussed include definitions, risk factors, the diagnostic modalities and treatment options.

Published
2023

28. Vitamin D supplementation not useful for all older people

Author

Krul-Poel, Yvonne H. M., Lems, Willem F., de Jongh, Renate T., Rheumatology, AII - Inflammatory diseases, AMS - Musculoskeletal Health, AMS - Tissue Function & Regeneration, Internal medicine, AMS - Ageing & Vitality, and Amsterdam Gastroenterology Endocrinology Metabolism

Abstract

An estimated 1.5 million Dutch people take vitamin D supplements on prescription, not including those who take multivitamins or vitamin D over the counter. Yet, controversial health benefits of vitamin D supplementation in the general population continues, often explained with not adequately powered studies, combination therapy with calcium, high bolus doses of vitamin D and poor study designs. Recently, the VITAL study does not show an effect in fracture incidence after treatment with daily vitamin D (2000IU) compared to placebo. However, zooming into the results a positive trend is observed in patients with a fragility fracture and/or using anti-osteoporosis medication. Additionally this study does not rule out a positive effect of vitamin D supplementation in severe vitamin D deficiency and high fracture risk patients.

Published
2023

34. [18F]Fluoride PET provides distinct information on disease activity in ankylosing spondylitis as compared to MRI and conventional radiography

Author

de Jongh, Jerney, primary, Verweij, Nicki J. F., additional, Yaqub, Maqsood, additional, van Denderen, Christiaan J., additional, van der Horst-Bruinsma, Irene E., additional, Bot, Joost C. J., additional, Boden, Bouke J. H., additional, Hemke, Robert, additional, Smithuis, Frank F., additional, Lems, Willem F., additional, Lammertsma, Adriaan A., additional, Voskuyl, Alexandre E., additional, Boers, Maarten, additional, Zwezerijnen, Gerben J. C., additional, and van der Laken, Conny J., additional

Published
2022
Full Text
View/download PDF

35. SARS-CoV-2 breakthrough infections in patients with immune-mediated inflammatory diseases during the omicron dominant period

Author

Boekel, Laura, primary, Besten, Yaëlle R, additional, Hooijberg, Femke, additional, Wartena, Rosa, additional, Steenhuis, Maurice, additional, Vogelzang, Erik, additional, Leeuw, Maureen, additional, Atiqi, Sadaf, additional, Tas, Sander W, additional, Lems, Willem F, additional, van Ham, S Marieke, additional, Eftimov, Filip, additional, Stalman, Eileen W, additional, Wieske, Luuk, additional, Kuijpers, Taco W, additional, Voskuyl, Alexandre E, additional, van Vollenhoven, Ronald F, additional, Gerritsen, Martijn, additional, Krieckaert, Charlotte, additional, Rispens, Theo, additional, Boers, Maarten, additional, Nurmohamed, Mike T, additional, and Wolbink, Gertjan, additional

Published
2022
Full Text
View/download PDF

37. Favourable effect of a ‘second hit’ after 13 weeks in early RA non-responders: the Amsterdam COBRA treat-to-target randomized trial

Author

Hartman, Linda, primary, Rasch, Linda A, additional, Turk, Samina A, additional, ter Wee, Marieke M, additional, Kerstens, Pit J S M, additional, van der Laken, Conny J, additional, Nurmohamed, Michael T, additional, van Schaardenburg, Dirkjan, additional, van Tuyl, Lilian H D, additional, Voskuyl, Alexandre E, additional, Boers, Maarten, additional, and Lems, Willem F, additional

Published
2022
Full Text
View/download PDF

41. Association Between Measures of Muscle Strength and Performance of Daily Activities in Patients with Knee Osteoarthritis

Author

de Zwart, Arjan, Dekker, Joost, Verberne, Simon, Roorda, Leo D., van der Esch, Martin, Lems, Willem F., van der Leeden, Marike, Psychiatry, Rehabilitation medicine, APH - Aging & Later Life, APH - Mental Health, APH - Health Behaviors & Chronic Diseases, AMS - Rehabilitation & Development, Rheumatology, AII - Inflammatory diseases, AMS - Musculoskeletal Health, AMS - Tissue Function & Regeneration, AMS - Ageing & Vitality, and APH - Societal Participation & Health

Subjects
Rehabilitation, Humans, Physical Therapy, Sports Therapy and Rehabilitation, General Medicine, Muscle Strength, Walking, Middle Aged, Osteoarthritis, Knee, Aged
Abstract

Objectives: Most studies of knee osteoarthritis use isokinetic peak strength as a measure of muscle strength. However, estimated one-repetition maximum (1-RM) may have a stronger relationship than isokinetic peak strength with daily activities. The aim of this study was to test the following hypotheses: first, the estimated 1-RM is more strongly associated than isokinetic peak strength with daily activities; and secondly, the estimated 1-RM is most strongly associated with the 6-minute walk test (6MWT), followed by the Get Up and Go test (GUG test) and the stair-climb test.Methods: Data were used for 177 patients with knee osteoarthritis from a randomized controlled trial on improving muscle strength. The patients had a mean age of 67.6 ± 5.8 years. Isokinetic peak strength was measured using a dynamometer, 1-RM was estimated with the 10-RM test, and physical performance was measured with the 6-minute walk test (6MWT), get-up and go test (GUG) test and stair-climb test, at the start and end of 12 weeks of resistance training. Linear regression analyses provided standardized betas (β) that were comparable between the different associations between measures of muscle strength and daily activities. Results: Compared with the estimated 1-RM, isokinetic peak strength was more strongly associated with all performance-based measures. The associations between the estimated 1-RM and performance-based tests were not ranked in the order hypothesized (6MWT, GUG test, stair-climb test).Conclusion: Contrary to the first hypothesis, isokinetic peak strength showed stronger associations with all daily activities than did estimated 1-RM. In addition, the second hypothesis regarding the activity-specific pattern for the 1-RM with regards walking, chair rising and stair climbing measurements was not confirmed. LAY ABSTRACTIn patients with knee osteoarthritis, greater muscle strength in the upper leg is linked with better performance in daily activities. To test muscle strength, peak muscle strength is usually measured. This study hypothesized that another test (the one-repetition maximum test) would be a more relevant measure. However, this was not confirmed, and therefore peak muscle strength remains the best measure of muscle strength at present.

Published
2022

42. Development of prediction models to select older RA patients with comorbidities for treatment with chronic low-dose glucocorticoids

Author

Hartman, Linda, primary, da Silva, José A P, additional, Buttgereit, Frank, additional, Cutolo, Maurizio, additional, Opris-Belinski, Daniela, additional, Szekanecz, Zoltan, additional, Masaryk, Pavol, additional, Voshaar, Marieke J H, additional, Heymans, Martijn W, additional, Lems, Willem F, additional, van der Heijde, Désirée M F M, additional, and Boers, Maarten, additional

Published
2022
Full Text
View/download PDF

46. Favourable effect of a 'second hit' after 13 weeks in early RA non-responders: the Amsterdam COBRA treat-to-target randomized trial.

Author

Hartman, Linda, Rasch, Linda A, Turk, Samina A, Wee, Marieke M ter, Kerstens, Pit J S M, Laken, Conny J van der, Nurmohamed, Michael T, Schaardenburg, Dirkjan van, Tuyl, Lilian H D van, Voskuyl, Alexandre E, Boers, Maarten, and Lems, Willem F

Subjects
RHEUMATOID arthritis risk factors, COMBINATION drug therapy, PREDNISOLONE, CONFIDENCE intervals, CLASSIFICATION, PATIENTS, TREATMENT effectiveness, METHOTREXATE, RHEUMATOID arthritis, DRUG therapy, RESEARCH funding, HYDROXYCHLOROQUINE, STATISTICAL sampling, ADVERSE health care events, EARLY medical intervention, SULFONAMIDES
Abstract

Objective The aim of this study was to investigate the effect of treat-to-target combination therapy with intensification at 13 weeks in early RA. Methods Early RA patients were classified as being at high or low risk of worsening RA based on disease activity and prognostic factors. High-risk patients received COBRA-light (prednisolone 30 mg/day tapered to 7.5 mg/day, MTX increasing to 25 mg/week), and low-risk patients received MTX monotherapy increasing to 25 mg/week. The primary outcome (target) was DAS44 < 1.6 or EULAR good response at 26 weeks. At 13 weeks, non-responders were randomized to (open-label) intensification [high-risk patients: prednisolone 60 mg/day tapered to 7.5 mg/day, addition of SSZ (2 g/day) and HCQ (400 mg/day); low-risk patients: prednisolone 30 mg/day tapered to 7.5 mg/day] or continuation. Results In the high-risk group (n  = 150), 110 patients (73%) reached the target at 13 weeks, and 9 dropped out. Non-responders were randomized to intensification (n  = 15) or continuation (n  = 16), and after 26 weeks, 12 (80%) vs 7 (44%) of these, respectively, reached the target [difference: 36%, (95% CI 2%, 71%); P  = 0.04]. In the low-risk group (n  = 40), 17 (43%) reached the target. Non-responders were randomized to intensification (n  = 8) or continuation (n  = 7); 4 vs 3, respectively, reached the target. Adverse event rates were higher in the high-risk group, and higher in the intensification subgroup of that group. Serious adverse events were rare. Protocol violations were frequent and mostly led to mitigation of actual treatment intensification. Conclusion Initial combination therapy was very successful in high-risk RA, and early intensification was beneficial in patients not reaching the strict target. The low-risk group was too small for drawing conclusions. In routine practice, adherence to early intensification based on strict targets is difficult. Trial registration Netherlands Trial Register (NTR), NL4393, https://www.trialregister.nl/. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

47. Development of prediction models to select older RA patients with comorbidities for treatment with chronic low-dose glucocorticoids.

Author

Hartman, Linda, Silva, José A P da, Buttgereit, Frank, Cutolo, Maurizio, Opris-Belinski, Daniela, Szekanecz, Zoltan, Masaryk, Pavol, Voshaar, Marieke J H, Heymans, Martijn W, Lems, Willem F, Heijde, Désirée M F M van der, and Boers, Maarten

Subjects
DISEASE progression, GLUCOCORTICOIDS, PREDNISOLONE, PATIENT selection, RESEARCH methodology, REGRESSION analysis, RHEUMATOID arthritis, RESEARCH funding, PREDICTION models, LOGISTIC regression analysis, COMORBIDITY, OLD age
Abstract

Objective To develop prediction models for individual patient harm and benefit outcomes in elderly patients with RA and comorbidities treated with chronic low-dose glucocorticoid therapy or placebo. Methods In the Glucocorticoid Low-dose Outcome in Rheumatoid Arthritis (GLORIA) study, 451 RA patients ≥65 years of age were randomized to 2 years 5 mg/day prednisolone or placebo. Eight prediction models were developed from the dataset in a stepwise procedure based on prior knowledge. The first set of four models disregarded study treatment and examined general predictive factors. The second set of four models was similar but examined the additional role of low-dose prednisolone. In each set, two models focused on harm [the occurrence of one or more adverse events of special interest (AESIs) and the number of AESIs per year) and two on benefit (early clinical response/disease activity and a lack of joint damage progression). Linear and logistic multivariable regression methods with backward selection were used to develop the models. The final models were assessed and internally validated with bootstrapping techniques. Results A few variables were slightly predictive for one of the outcomes in the models, but none were of immediate clinical value. The quality of the prediction models was sufficient and the performance was low to moderate (explained variance 12–15%, area under the curve 0.67–0.69). Conclusion Baseline factors are not helpful in selecting elderly RA patients for treatment with low-dose prednisolone given their low power to predict the chance of benefit or harm. Trial registration https://clinicaltrials.gov ; NCT02585258. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

48. [18F]Fluoride PET provides distinct information on disease activity in ankylosing spondylitis as compared to MRI and conventional radiography.

Author

de Jongh, Jerney, Verweij, Nicki J. F., Yaqub, Maqsood, van Denderen, Christiaan J., van der Horst-Bruinsma, Irene E., Bot, Joost C. J., Boden, Bouke J. H., Hemke, Robert, Smithuis, Frank F., Lems, Willem F., Lammertsma, Adriaan A., Voskuyl, Alexandre E., Boers, Maarten, Zwezerijnen, Gerben J. C., and van der Laken, Conny J.

Subjects
ANKYLOSING spondylitis, MAGNETIC resonance imaging, BONE marrow, RADIOGRAPHY, EDEMA
Abstract

Purpose: To relate [18F]fluoride uptake on PET with abnormalities on magnetic resonance imaging (MRI) and conventional radiography (CR) in ankylosing spondylitis (AS) patients. Methods: Ten clinically active AS patients (female 6/10, age 38 ± 11 years) were included, and both spine and SI-joints were examined. PET scans were dichotomously scored for enhanced [18F]fluoride uptake, MRI scans were scored for fatty lesions, erosions, ankylosis, and bone marrow edema (BME), and CR was scored for erosions, syndesmophytes, and ankylosis. The overlap of lesions across all modalities was evaluated through univariate and multivariate analyses using a generalized mixed model. Results: In the spine, 69 lesions with enhanced [18F]fluoride uptake, 257 MRI lesions, and 88 CR lesions were observed. PET lesions were mostly located in costovertebral and facet joints, outside the field of view (FOV) of the MRI and CR. However, PET lesions inside the FOV of MRI and CR partially showed no abnormality on MRI and CR. In lesions with abnormalities on multiple modalities, both univariate and multivariate analysis showed that PET activity had the strongest association with BME on MRI and ankylosis on CR. In the SI joints, 15 lesions (75%) with PET uptake were found, with 87% showing abnormalities on MRI and CR. Conclusion: [18F]fluoride PET lesions are often found outside the scope of MRI and CR, and even in the same location show only partial overlap with abnormalities on MRI (especially BME) and CR (especially ankylosis). This suggests that [18F]fluoride PET partially visualizes aspects of AS separate from MRI and CR, providing novel information. Clinical trial registration: NL43223.029.13 registered at 02-05-2013. https://www.toetsingonline.nl/to/ccmo_search.nsf/fABRpop?readform&unids=C1257BA2002CC066C1257B4E0049A65A [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results